Company: MYGN
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0000899923-25-000028
Chunk: 99

Company: MYRIAD GENETICS INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 99
---
 M.D., constitute a class with a term ending at the 2026 Annual Meeting (the “Class III Directors”). At each Annual Meeting, directors are elected for a term to expire at the third succeeding Annual Meeting after their election to succeed those directors whose terms are expiring at the Annual Meeting. On February 24, 2025, Mr. Diaz resigned from the Board effective April 30, 2025. Subsequently, the Board appointed Samraat S. Raha to the Board as a Class II Director, effective April 30, 2025, to fill the vacancy that resulted from Mr. Diaz's resignation.

The Board accepted the recommendation of the NGC and unanimously resolved to nominate Heiner Dreismann, Ph.D., Samraat S. Raha, and Colleen F. Reitan for election at the Annual Meeting for a term to serve until the 2028 Annual Meeting, and until their successors have been elected and qualified, or until their earlier death, resignation, retirement or removal. In determining to nominate these directors for another term to serve until the 2028 Annual Meeting, the NGC and the Board considered, among other things, their qualifications, experiences, and contributions to Myriad. With respect to Dr. Dreismann, the Board and NGC considered his business and management experience, his tenure on the Board since June 2010, and his contributions to our research and development, product innovation, and long-term growth strategy. Regarding Mr. Raha, as part of his appointment as President and Chief Executive Officer, effective April 30, 2025, we agreed to nominate Mr. Raha for re-election to the Board for any succeeding term or terms as a Board member that commence during the term of his employment. In the case of Ms. Reitan, the Board and NGC considered her extensive reimbursement and managed care experience, as well as her service on the Board since 2019, and her contributions to our long-term growth strategy, reimbursement initiatives, risk management, and governance.

Unless a stockholder has indicated otherwise on the proxy, the shares represented by a valid proxy will be voted FOR the election of Heiner Dreismann, Ph.D., Samraat S. Raha, and Colleen F. Reitan as directors. In the event that any nominee should become unable or unwilling to serve, the shares represented by a valid proxy will be voted for the election of another person who the Board recommends, unless the Board chooses to reduce the number of directors